Chlorthalidone with potassium citrate decreases calcium oxalate stones and increases bone quality in genetic hypercalciuric stone-forming rats
- 5 January 2021
- journal article
- research article
- Published by Elsevier BV in Kidney International
- Vol. 99 (5), 1118-1126
- https://doi.org/10.1016/j.kint.2020.12.023
Abstract
No abstract availableFunding Information
- National Institutes of Health
This publication has 41 references indexed in Scilit:
- Chlorthalidone improves vertebral bone quality in genetic hypercalciuric stone-forming ratsJournal of Bone and Mineral Research, 2011
- Nephrolithiasis-associated bone disease: pathogenesis and treatment optionsKidney International, 2011
- Pharmacotherapy of urolithiasis: evidence from clinical trialsKidney International, 2011
- Genetic Hypercalciuric Stone-Forming Rats Have a Primary Decrease in BMD and StrengthJournal of Bone and Mineral Research, 2009
- Thiosulfate Reduces Calcium Phosphate NephrolithiasisJournal of the American Society of Nephrology, 2009
- Isolation and Confirmation of a Calcium Excretion Quantitative Trait Locus on Chromosome 1 in Genetic Hypercalciuric Stone-Forming Congenic RatsJournal of the American Society of Nephrology, 2006
- Thiazides Reduce Brushite, but not Calcium Oxalate, Supersaturation, and Stone Formation in Genetic Hypercalciuric Stone–Forming RatsJournal of the American Society of Nephrology, 2005
- Relationship between supersaturation and crystal inhibition in hypercalciuric ratsKidney International, 1997
- Alkali absorption and citrate excretion in calcium nephrolithiasisJournal of Bone and Mineral Research, 1993
- Chlorthalidone promotes mineral retention in patients with idiopathic hypercalciuriaKidney International, 1988